Bright Minds Biosciences バランスシートの健全性

財務の健全性基準チェック /66

Bright Minds Biosciencesの総株主資本はCA$6.1M 、総負債はCA$0.0で、負債比率は0%となります。総資産と総負債はそれぞれCA$6.3MとCA$178.6Kです。

主要情報

負債資本比率

CA$0

負債

インタレスト・カバレッジ・レシオ	n/a
現金	CA$6.19m
エクイティ	CA$6.10m
負債合計	CA$178.63k
総資産	CA$6.28m

財務の健全性に関する最新情報

Companies Like Bright Minds Biosciences (CSE:DRUG) Can Afford To Invest In Growth

Oct 16

Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

Aug 19

We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

Mar 07

We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

Nov 04

Recent updates

Companies Like Bright Minds Biosciences (CSE:DRUG) Can Afford To Invest In Growth

Oct 16

Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

Aug 19

We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

Mar 07

We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

Nov 04

財務状況分析

短期負債: DRUGの短期資産 ( CA$6.3M ) が短期負債 ( CA$178.6K ) を超えています。

長期負債: DRUGには長期負債はありません。

デット・ツー・エクイティの歴史と分析

負債レベル: DRUGは負債がありません。

負債の削減: DRUG過去 5 年間負債を抱えていません。

貸借対照表

キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: DRUGは、現在のフリーキャッシュフローに基づき、1 年以上にわたって十分なキャッシュランウェイを有しています。

キャッシュランウェイの予測: DRUGは、フリーキャッシュフローが毎年17 % の歴史的率で減少し続ける場合、 1.4年間十分なキャッシュランウェイを有しています。

Bright Minds Biosciences バランスシートの健全性

財務の健全性 基準チェック /66

主要情報

財務の健全性に関する最新情報

Companies Like Bright Minds Biosciences (CSE:DRUG) Can Afford To Invest In Growth

Bright Minds Goes for 5:1 Shares Consolidation, Hopes to Regain Nasdaq Compliance

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

Recent updates

Bright Minds Biosciences Inc. announced that it has received $34.999973 million in funding from a group of investors

Independent Director exercised options to buy CA$1.1m worth of stock.

Bright Minds Biosciences Inc. announced that it expects to receive $35 million in funding

Bright Minds Biosciences Inc. Announces Positive Data from the Preclinical Testing of BMB-201

Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study Using its Artificial Intelligence, FDA-Cleared BNA™? Technology

Companies Like Bright Minds Biosciences (CSE:DRUG) Can Afford To Invest In Growth

High number of new and inexperienced directors

New major risk - Financial position

High number of new and inexperienced directors

Bright Minds Biosciences Inc., Annual General Meeting, Mar 22, 2024

Less than half of directors are independent

Bright Minds Biosciences Inc. announced that it expects to receive $0.9 million in funding

New major risk - Market cap size

Bright Minds Biosciences Inc. Announces Positive qEEG (Quantitative Electroencephalogram) Data from Its First-In-Human Phase 1 Study of Lead Compound, Bmb-101

Bright Minds Biosciences Inc. Announces Successful Completion of its Three-Part Phase 1 Study of BMB-101

Less than half of directors are independent

Bright Minds Goes for 5:1 Shares Consolidation, Hopes to Regain Nasdaq Compliance

Bright Minds Biosciences Inc. Announces Appointment of David Weiner as Non-Executive Director

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Bright Minds Biosciences Inc. Announces Resignation of Williamson from Board of Directors and Audit Committee

Bright Minds Biosciences Inc., Annual General Meeting, Mar 24, 2023

Bright Minds Biosciences Inc. Announces the Resignation of Doug Williamson from Board of Directors

Bright Minds Biosciences Inc. announced that it expects to receive CAD 2.05 million in funding

Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer, Effective December 1, 2022

High number of new and inexperienced directors

Bright Minds Biosciences Announces Executive Changes

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Bright Minds Biosciences Inc. has completed a Composite Units Offering in the amount of CAD 4.0012 million.

Bright Minds Biosciences Inc. has completed a Composite Units Offering in the amount of CAD 4.0012 million.

Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

Bright Minds Biosciences Announces Changes to Its Executive Leadership Team

High number of new and inexperienced directors

We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

Bright Minds Biosciences Provides Scientific Update on Its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

High number of new and inexperienced directors

Bright Minds Biosciences Inc. Provides Scientific Update

CEO & Director recently bought CA$116k worth of stock

Bright Minds Biosciences Inc., Annual General Meeting, May 18, 2021

Bright Minds Biosciences Inc. has completed a Composite Units Offering in the amount of CAD 25.00371 million.

Bright Minds Biosciences Inc. Proprietary 5-HT2C Agonist Shows an Over 50% Decrease in Opioid Self-Administration in a Predictive Rodent Model

Bright Minds Biosciences Proprietary 5-HT2C Agonists Show Significant Reduction in Binge Eating

Bright Minds Biosciences Announces Scientific Advisory Team Appointment

財務状況分析

デット・ツー・エクイティの歴史と分析

貸借対照表

キャッシュ・ランウェイ分析

健全な企業の発掘

財務の健全性基準チェック /66